ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. SUCCESSFULLY LISTED ON HKEX
Latest Update:
5 th July, 2021

On July 5, 2021, the nerve and peripheral vascular interventional medical devices market leader ─ ─ Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge"or the" company ", stock code: 2190) on the stock exchange of Hong Kong limited (" the Hong Kong stock exchange ") the motherboard for trading, buying and selling each unit is 500 shares H shares.

The company's share price peaked at HK $60.80 and closed at HK $60.00, about 40.52% higher than the offer price of HK $42.70. About 58.97 million shares traded for about HK $3.34 billion.

As the financial pr consultant team of the company, Porda Havas participated in the whole process of the company's listing, including the maintenance of domestic and foreign media relations, the design and production of listing publicity materials, and the holding of listing celebrations, helping the company to be listed in Hong Kong.

Dr. Zhong Zhao, founder, Chairman, Executive Director and CEO of Zylox-Tonbridge Medical Technology Co., Ltd., said, "Today, IT is a great pleasure to join you to witness the successful listing of Zylox-Tonbridge on the Hong Kong Stock Exchange. I would like to take this opportunity to express my sincere gratitude to all staff for their hard work, doctors and patients for their trust, shareholders for their support, intermediaries, HKEX, SFC and all partners. Do poineering work up to now, nearly ten years, still do not forget the beginner's mind, the bridge, proceed from the product itself, with innovative ideas and solid technology to build high quality medical equipment and the complete solution, on the way of commercial success step. In the future, we will be dedicated to all of the patients with high ratio of medical equipment and services, to protect human health!

About Zylox-Tonbridge Medical Technology Co., Ltd.

Zylox-Tonbridge Medical Technology Co., Ltd., is the market leader in Neurological and peripheral vascular interventional medical devices in China. Since its establishment in 2012, it has established a full range of solutions in neurological and peripheral vascular interventional medical devices and developed 45 products and product portfolio candidates. The company's current treatment areas include acute ischemic stroke, intracranial aneurysms, carotid stenosis, peripheral arterial and venous diseases, and dialysis-related diseases. According to Frost Sullivan, the company is the only domestic company in the field of neurovascular interventional medical devices that is developing a full range of products in the major neurovascular categories (i.e., ischemic, hemorrhagic, stenosis, carotid artery, vascular access devices). In the field of peripheral vascular interventional medical devices, the company has the most comprehensive product portfolio and the most approvals from the State Medical Products Administration among the domestic players in China.

Latest Update:
5 th July, 2021